Compare Mesoblast Limited (MESO) vs Oracle Corporation (ORCL) Price & Performance

Mesoblast LimitedTrade

Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Oracle Corporation — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.21B), while Oracle Corporation trades at $147.4 (market cap $419.05B). The key difference: Oracle Corporation is far larger — about 189.6× Mesoblast Limited's market cap, and Oracle Corporation pays a 1.37% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

	MESO	ORCL
Market Cap	$2.21B	$419.05B
Sector	Technology	Technology
52-Week High	$20.96	$328.33
52-Week Low	$12.88	$114.99
Enterprise Value	$2.21B	$548.30B
Dividend Yield	—	1.37%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

No Aura AI signal available yet.

Oracle Corporation

Oracle (ORCL) trades at $145.45, down 1.02% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.11 beating expectations of $1.96, and fundamentals show robust revenue growth, reaching $57.4 billion in 2025, and high profitability with a net margin of 25.37%. Recent news highlights Oracle's AI infrastructure growth and a legal investigation into insider conduct.

Oracle's outlook is positive due to AI-driven demand and consistent earnings outperformance, supported by a consensus analyst price target of $253.63. Key risks include high valuation multiples, rising debt levels, and competitive pressures in cloud services. The stock offers growth potential but requires monitoring of execution risks and market sentiment shifts.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MESO

View details →

ORCL

Nebius shares jump 3.7% as NVIDIA backs $500B AI cloud fund, Oracle slips amid competitive pressure.24/7 Wall Street · 20 hours agoBullish Oracle poised for 40% gain as AI cloud growth and backlog surge drive bullish outlook24/7 Wall Street · 23 hours agoBullish Oracle launches AI-powered HR tools in Fusion Cloud to boost workforce development and talent management.PRNewsWire · 1 day agoBullish View details →

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.